REGN logo Regeneron Pharmaceuticals +
Regeneron Pharmaceuticals
+

Regeneron Pharmaceuticals (REGN) Business News

Track Regeneron Pharmaceuticals in real time with a live news feed covering Regeneron Pharmaceuticals stock news, official press releases, company announcements, and an archive of historical Regeneron Pharmaceuticals news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
1:34 PM | Monday | Oct 12, 2026 Benzinga

Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth

News Thumbnail
1:10 PM | Monday | Oct 12, 2026 Zacks Investment Research

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

News Thumbnail
12:06 PM | Monday | Oct 12, 2026 GlobeNewsWire

Pasatruâ„¢ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

News Thumbnail
10:41 AM | Friday | Oct 9, 2026 Zacks Investment Research

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

News Thumbnail
10:41 AM | Friday | Oct 9, 2026 Zacks Investment Research

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

News Thumbnail
9:02 AM | Tuesday | Oct 6, 2026 Defense World

Regeneron (NASDAQ: REGN) signs $1.0 billion Sanofi pact for new antibodies

News Thumbnail
7:06 AM | Tuesday | Oct 6, 2026 Defense World

Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Central Pacific Bank Trust Division

News Thumbnail
7:00 AM | Tuesday | Oct 6, 2026 GlobeNewsWire

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

News Thumbnail
10:46 AM | Friday | Oct 2, 2026 Zacks Investment Research

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

News Thumbnail
6:15 AM | Friday | Oct 2, 2026 Defense World

Reviewing Rigel Pharmaceuticals (NASDAQ:RIGL) & Regeneron Pharmaceuticals (NASDAQ:REGN)

News Thumbnail
11:35 AM | Thursday | Oct 1, 2026 GlobeNewsWire

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

News Thumbnail
11:30 AM | Thursday | Oct 1, 2026 GlobeNewsWire

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

News Thumbnail
11:02 AM | Thursday | Oct 1, 2026 MarketBeat

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion

News Thumbnail
10:50 AM | Thursday | Oct 1, 2026 Zacks Investment Research

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

News Thumbnail

Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth

Benzinga

1:34 PM | Monday | Oct 12, 2026

news photo
Loading...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Monday shared encouraging 84-week findings from the Phase 3 OPTIMA trial for its drug Pasatru (garetosmab-grts).

Read full article redirect
1:34 PM | Monday | Oct 12, 2026

Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth

Benzinga

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Monday shared encouraging 84-week findings from the Phase 3 OPTIMA trial for its drug Pasatru (garetosmab-grts).

Read full article arrow
News Thumbnail
1:10 PM | Monday | Oct 12, 2026

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

Zacks Investment Research

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read full article arrow
News Thumbnail
12:06 PM | Monday | Oct 12, 2026

Pasatruâ„¢ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

GlobeNewsWire

Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP Late-breaking data presented at ASBMR show sustained efficacy of Pasatru and a consistent safety profile from weeks 56 to 84, supporting long-term disease control TARRYTOWN, N.Y., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatruâ„¢ (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).

Read full article arrow
News Thumbnail
10:41 AM | Friday | Oct 9, 2026

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

Zacks Investment Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read full article arrow
News Thumbnail
10:41 AM | Friday | Oct 9, 2026

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

Zacks Investment Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read full article arrow
News Thumbnail
9:02 AM | Tuesday | Oct 6, 2026

Regeneron (NASDAQ: REGN) signs $1.0 billion Sanofi pact for new antibodies

Defense World

What happened Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said on October 1, 2026, it entered the Sixth Amendment with Sanofi. Under the amendment, Sanofi will make a $1.0 billion upfront payment. The companies also agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies that target IL-13, IL-4, IL-4R and IL-4xIL-13.
Global profits on sales of

Read full article arrow
News Thumbnail
7:06 AM | Tuesday | Oct 6, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Central Pacific Bank Trust Division

Defense World

Central Pacific Bank Trust Division raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 90.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,687 shares of the biopharmaceutical company's stock after purchasing an additional 1,275 shares during the period.

Read full article arrow
News Thumbnail
7:00 AM | Tuesday | Oct 6, 2026

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

GlobeNewsWire

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation

Read full article arrow
News Thumbnail
10:46 AM | Friday | Oct 2, 2026

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

Zacks Investment Research

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.

Read full article arrow
News Thumbnail
6:15 AM | Friday | Oct 2, 2026

Reviewing Rigel Pharmaceuticals (NASDAQ:RIGL) & Regeneron Pharmaceuticals (NASDAQ:REGN)

Defense World

Rigel Pharmaceuticals (NASDAQ: RIGL - Get Free Report) and Regeneron Pharmaceuticals (NASDAQ: REGN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Valuation and Earnings This table compares Rigel Pharmaceuticals

Read full article arrow
News Thumbnail
11:35 AM | Thursday | Oct 1, 2026

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

GlobeNewsWire

LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy

Read full article arrow
News Thumbnail
11:30 AM | Thursday | Oct 1, 2026

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

GlobeNewsWire

In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment  A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and is in press with The Lancet TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss in people living with obesity.

Read full article arrow
News Thumbnail
11:02 AM | Thursday | Oct 1, 2026

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion

MarketBeat

Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framework for the assets.

Read full article arrow
News Thumbnail
10:50 AM | Thursday | Oct 1, 2026

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

Zacks Investment Research

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

Read full article arrow
News Thumbnail